iTeos Therapeutics (NASDAQ:ITOS) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a report issued on Tuesday,RTT News reports. The firm currently has a $25.00 price target on the stock.

A number of other research analysts also recently commented on ITOS. HC Wainwright reiterated a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a report on Monday, September 16th. JPMorgan Chase & Co. dropped their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, Wells Fargo & Company began coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective for the company.

iTeos Therapeutics Stock Performance

Shares of ITOS opened at $9.19 on Tuesday. The stock has a 50-day simple moving average of $10.84 and a 200-day simple moving average of $14.07. iTeos Therapeutics has a 1 year low of $8.41 and a 1 year high of $18.75. The stock has a market capitalization of $335.62 million, a PE ratio of -3.06 and a beta of 1.39.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ITOS. nVerses Capital LLC boosted its stake in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after buying an additional 1,700 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after acquiring an additional 2,646 shares during the period. Quest Partners LLC grew its stake in shares of iTeos Therapeutics by 914.7% in the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after purchasing an additional 9,934 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of iTeos Therapeutics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after purchasing an additional 690 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of iTeos Therapeutics by 35.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after purchasing an additional 3,172 shares during the period. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.